Process for screening madicine of antivirus

A screening method and drug technology, applied in the direction of biochemical equipment and methods, microbial determination/inspection, etc., can solve the problems of lack of screening methods, no screening methods, etc.

Inactive Publication Date: 2007-07-04
GUANGXI UNIV
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But for most RNA viruses, ideal screening methods are still very lacking
Especially in the development of drugs against plant viruses and fungal virus diseases, there is currently no simple, fast and efficient screening method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for screening madicine of antivirus
  • Process for screening madicine of antivirus
  • Process for screening madicine of antivirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Acyclovir (100 mg / tablet) was prepared into a 160 mg / ml solution with sterilized water, and the insoluble part was removed by centrifugation. The drug was added into the PDA solid medium according to the gradient of 32mg / ml, 3.2mg / ml, and 0.32mg / ml. Inoculate EP721 and culture at room temperature for 7 days. The results showed that the 3.2mg / ml drug concentration made the fungal colony obviously turn orange (Figure 2-A), which was close to the level when there was no virus, indicating that the symptoms had been significantly relieved. And when the drug concentration of 32mg / ml, except that bacterial colony turns orange, its growth has been obviously inhibited.

Embodiment 2

[0034] Quick gram (amantadine hydrochloride 100mg / grain), get 4 capsules and be mixed with the solution of 10ml with sterile water, centrifuge to remove insoluble matter. Drugs were added to the PDA solid medium according to three concentration gradients of 160, 320, and 640ug / ml. Inoculate EP721 and culture at room temperature for 7 days. The results showed that the drug concentration of 320ug / ml made the bacterial colonies of the fungi obviously turn orange (Fig. 3-B), while at the drug concentration of 640ug / ml, the growth of the bacterial colonies was obviously inhibited except that they turned orange.

Embodiment 3

[0036] Morpholine guanidine hydrochloride (100mg / tablet), get 100 tablets and dissolve with 50ml sterile water, and centrifuge to remove insoluble matter. Drugs were added into PDA solid medium according to three gradients of 90ug / ml, 900ug / ml, and 9000ug / ml, inoculated with EP721, and incubated at room temperature for 7 days. The results showed that the drug dosage of 900ug / ml made the colony of the fungus obviously turn orange, which was close to the level when there was no virus, indicating that the symptoms had been obviously relieved. And on the flat plate of 9000ug / ml, except that bacterial colony turns orange, its growth has been obviously inhibited (Fig. 4). Further extraction of dsRNA verification, with the increase of drug concentration, the concentration of dsRAN decreased slightly (Figure 5).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

A method for screening antivirus medicine is based on a test system composed of dual-chain RNA virus and its natural host (chestnut blight bacterium). The chestnut blight bacterium EP-721(-) without virus shows orange color and the chestnut blight bacterium carrying virus CHV1-EP721 shows white color. After the latter is treated by an antivirus medicine, the effect of said medicine can be determined according to the color variation.

Description

technical field [0001] The invention belongs to the technical field of antiviral drug screening. In particular, it relates to a screening method for anti-RNA virus drugs. Background technique [0002] Drug screening is a crucial link in the research and development of new drugs. Simple and effective screening methods can greatly shorten the process of new drug development. Routine drug screening begins with cell plaque experiments, and enters clinical trials after evaluating the effectiveness and toxicity of animal models. Modern drug screening has added methods such as cytopathic inhibition experiments, in vitro reaction inhibition experiments, etc. [1-3] . Each method has a special design basis for a specific virus, and each has advantages and disadvantages. For example, the advantage of in vitro reaction inhibition experiment is that it is fast, but it is necessary to obtain virus and host-specific factors and establish a suitable test system in advance. [4-14] , and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/18
Inventor 陈保善林海燕戴璐
Owner GUANGXI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap